Literature DB >> 23095280

Myosin light chain phosphorylation is critical for adaptation to cardiac stress.

Sonisha A Warren1, Laura E Briggs, Huadong Zeng, Joyce Chuang, Eileen I Chang, Ryota Terada, Moyi Li, Maurice S Swanson, Stewart H Lecker, Monte S Willis, Francis G Spinale, Julie Maupin-Furlowe, Julie R McMullen, Richard L Moss, Hideko Kasahara.   

Abstract

BACKGROUND: Cardiac hypertrophy is a common response to circulatory or neurohumoral stressors as a mechanism to augment contractility. When the heart is under sustained stress, the hypertrophic response can evolve into decompensated heart failure, although the mechanism(s) underlying this transition remain largely unknown. Because phosphorylation of cardiac myosin light chain 2 (MLC2v), bound to myosin at the head-rod junction, facilitates actin-myosin interactions and enhances contractility, we hypothesized that phosphorylation of MLC2v plays a role in the adaptation of the heart to stress. We previously identified an enzyme that predominantly phosphorylates MLC2v in cardiomyocytes, cardiac myosin light-chain kinase (cMLCK), yet the role(s) played by cMLCK in regulating cardiac function in health and disease remain to be determined. METHODS AND
RESULTS: We found that pressure overload induced by transaortic constriction in wild-type mice reduced phosphorylated MLC2v levels by ≈40% and cMLCK levels by ≈85%. To examine how a reduction in cMLCK and the corresponding reduction in phosphorylated MLC2v affect function, we generated Mylk3 gene-targeted mice and transgenic mice overexpressing cMLCK specifically in cardiomyocytes. Pressure overload led to severe heart failure in cMLCK knockout mice but not in mice with cMLCK overexpression in which cMLCK protein synthesis exceeded degradation. The reduction in cMLCK protein during pressure overload was attenuated by inhibition of ubiquitin-proteasome protein degradation systems.
CONCLUSIONS: Our results suggest the novel idea that accelerated cMLCK protein turnover by the ubiquitin-proteasome system underlies the transition from compensated hypertrophy to decompensated heart failure as a result of reduced phosphorylation of MLC2v.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23095280      PMCID: PMC3510779          DOI: 10.1161/CIRCULATIONAHA.112.116202

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  51 in total

Review 1.  Myosin light chain 2 into the mainstream of cardiac development and contractility.

Authors:  Richard L Moss; Daniel P Fitzsimons
Journal:  Circ Res       Date:  2006-08-04       Impact factor: 17.367

2.  Effect of diastolic pressure on MLC2v phosphorylation in the rat left ventricle.

Authors:  Carlos Hidalgo; Yiming Wu; Jun Peng; William F Siems; Kenneth B Campbell; Henk Granzier
Journal:  Arch Biochem Biophys       Date:  2006-08-14       Impact factor: 4.013

3.  Transmural dispersion of myofiber mechanics: implications for electrical heterogeneity in vivo.

Authors:  Hiroshi Ashikaga; Benjamin A Coppola; Bruce Hopenfeld; Eric S Leifer; Elliot R McVeigh; Jeffrey H Omens
Journal:  J Am Coll Cardiol       Date:  2007-02-09       Impact factor: 24.094

4.  Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy.

Authors:  Julie R McMullen; Fatemeh Amirahmadi; Elizabeth A Woodcock; Martina Schinke-Braun; Russell D Bouwman; Kimberly A Hewitt; Janelle P Mollica; Li Zhang; Yunyu Zhang; Tetsuo Shioi; Antje Buerger; Seigo Izumo; Patrick Y Jay; Garry L Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

Review 5.  Regulation of cardiac hypertrophy by intracellular signalling pathways.

Authors:  Joerg Heineke; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2006-08       Impact factor: 94.444

Review 6.  Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.

Authors:  Julie R McMullen; Garry L Jennings
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-04       Impact factor: 2.557

7.  Identification of cardiac-specific myosin light chain kinase.

Authors:  Jason Y Chan; Morihiko Takeda; Laura E Briggs; Megan L Graham; Jonathan T Lu; Nobuo Horikoshi; Ellen O Weinberg; Hiroki Aoki; Naruki Sato; Kenneth R Chien; Hideko Kasahara
Journal:  Circ Res       Date:  2008-01-17       Impact factor: 17.367

8.  A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart.

Authors:  Osamu Seguchi; Seiji Takashima; Satoru Yamazaki; Masanori Asakura; Yoshihiro Asano; Yasunori Shintani; Masakatsu Wakeno; Tetsuo Minamino; Hiroya Kondo; Hidehiko Furukawa; Kenji Nakamaru; Asuka Naito; Tomoko Takahashi; Toshiaki Ohtsuka; Koichi Kawakami; Tadashi Isomura; Soichiro Kitamura; Hitonobu Tomoike; Naoki Mochizuki; Masafumi Kitakaze
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

9.  Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.

Authors:  Abdullah Hacihanefioglu; Pinar Tarkun; Emel Gonullu
Journal:  Int J Hematol       Date:  2008-07-17       Impact factor: 2.490

Review 10.  Return to the fetal gene program protects the stressed heart: a strong hypothesis.

Authors:  Mitra Rajabi; Christos Kassiotis; Peter Razeghi; Heinrich Taegtmeyer
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

View more
  52 in total

Review 1.  Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.

Authors:  Rajesh Parsanathan; Sushil K Jain
Journal:  Metab Syndr Relat Disord       Date:  2019-10-16       Impact factor: 1.894

2.  Myosin light chain phosphorylation to the rescue.

Authors:  Henk L Granzier; Pieter P de Tombe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-08       Impact factor: 11.205

3.  Constitutive phosphorylation of cardiac myosin regulatory light chain in vivo.

Authors:  Audrey N Chang; Pavan K Battiprolu; Patrick M Cowley; Guohua Chen; Robert D Gerard; Jose R Pinto; Joseph A Hill; Anthony J Baker; Kristine E Kamm; James T Stull
Journal:  J Biol Chem       Date:  2015-03-02       Impact factor: 5.157

4.  Distinct sequences and post-translational modifications in cardiac atrial and ventricular myosin light chains revealed by top-down mass spectrometry.

Authors:  Zachery R Gregorich; Wenxuan Cai; Ziqing Lin; Albert J Chen; Ying Peng; Takushi Kohmoto; Ying Ge
Journal:  J Mol Cell Cardiol       Date:  2017-04-17       Impact factor: 5.000

5.  Phosphomimetic-mediated in vitro rescue of hypertrophic cardiomyopathy linked to R58Q mutation in myosin regulatory light chain.

Authors:  Sunil Yadav; Katarzyna Kazmierczak; Jingsheng Liang; Yoel H Sitbon; Danuta Szczesna-Cordary
Journal:  FEBS J       Date:  2018-12-01       Impact factor: 5.542

6.  Myosin light chain phosphorylation, novel targets to repair a broken heart?

Authors:  Danuta Szczesna-Cordary; Pieter P de Tombe
Journal:  Cardiovasc Res       Date:  2016-05-17       Impact factor: 10.787

7.  Cardiac myosin light chain is phosphorylated by Ca2+/calmodulin-dependent and -independent kinase activities.

Authors:  Audrey N Chang; Pravin Mahajan; Stefan Knapp; Hannah Barton; H Lee Sweeney; Kristine E Kamm; James T Stull
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-20       Impact factor: 11.205

Review 8.  Pseudophosphorylation of cardiac myosin regulatory light chain: a promising new tool for treatment of cardiomyopathy.

Authors:  Sunil Yadav; Danuta Szczesna-Cordary
Journal:  Biophys Rev       Date:  2017-01-25

Review 9.  Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations.

Authors:  Wenrui Huang; Danuta Szczesna-Cordary
Journal:  J Muscle Res Cell Motil       Date:  2015-09-18       Impact factor: 2.698

10.  Hypertrophic cardiomyopathy associated Lys104Glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice.

Authors:  Wenrui Huang; Jingsheng Liang; Katarzyna Kazmierczak; Priya Muthu; Divya Duggal; Gerrie P Farman; Lars Sorensen; Iraklis Pozios; Theodore P Abraham; Jeffrey R Moore; Julian Borejdo; Danuta Szczesna-Cordary
Journal:  J Mol Cell Cardiol       Date:  2014-06-30       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.